Slide 1: Investor Presentation August 2014
©) ChromaDex August 2014 Investor Presentation
Slide 2: Disclaimers
Disclaimers Safe Harbor ‘This presentation and other weten or oral statements made trom time to time by representatives of ChromaDex contain Yorwardooking statements” within the ‘meaning of Section 27A ofthe Secures Act of 1993, a5 amended, and Section Z1E of te Sacurties Exchange Act of 1884. Forwa
Slide 3: ChromaDex Overview
ChromaDex Overview is ChromaDex is an innovative ingredient technology company currently commercializing four patented and proprietary ingredient technologies which in aggregate address multi-billion- dollar markets. ( NIAGEN. suseKenar pleréPure ProC3G. | Gyanidin-3-glucoside ChromaDex’s unique bus
Slide 4: ChromaDex's Unique Business Model
ChromaDex’s Unique Business Model [4 Chemistry Business To Acqui Novel Ingredients » Established and growing brand +» Thousands of customers worldwide A « University research Provides Market « Customer order flow US 6. Market trends Proprietary products Patent protected Scientifically backed G >) Hi
Slide 5: ChromaDex's Unique Strategy Gives it First-mover Advantages
ChromaDex’s Unique Strategy Gives it First-mover ls Advantages in Acquiring Patented Ingredient Technologies a a me, Recess to Research << Insight to Consumer 4 Activity... Markets... XY \ f * over 250 University & Research / \, Over 1500 Industry Customers \. i Institute customers i ‘7 \ | Dartmout
Slide 6: ChromaDex Discovers, Acquires, & Develops Early-stage Proprietary Ingredient Technologies
ChromaDex Discovers, Acquires, & Develops Early-stage | ¢ Proprietary Ingredient Technologies and Commercializes a them in Multi-billion-dollar Markets Commercialize Discover novel, early-stage Exclusively license Develop ingredient Commercialize in mutti-billion- Ingredient Technologies, these ingr
Slide 7: Ingredient Market Opportunity
Ingredient Market Opportunity |@ Novel P iarkets um Market PMAccressable HM sates Markets, Market Size [ll Channels Dieta on EE - ee a rn =| =—_—s Ee Physician ProcaG. Cyanidin-3-glucoside ChromaDex markets novel ingredient technologies - not finished products. The initial sales cycle for its ingred
Slide 8: $62 Million Ingredient Agreement with 5LINX
In January 2014, ChromaDex Announced a | 8 $62 Million Ingredient Agreement with 5LINX® pSLINX’ ‘The premier business opportunity offering essential products & services people use everyday Four-year ingredient supply and brand licensing agreement valued at approximately $62 million. Hees + Under the
Slide 9: NIAGEN is the 1st and Only Commercially Available Nicotinamide Riboside
I Na \. ChromaDex’s NIAGEN™ is the 15* and Only | 9 y Commercially Available Nicotinamide Riboside | NIAGEN. * ChromaDex launched NIAGEN™ in May 2013. * Nicotinamide Riboside (NR) is a compound found naturally in milk and shown to boost nicotinamide adenine dinucleotide (NAD+) levels. NAD+ is a crit
Slide 10: NIAGEN is a Platform Ingredient Applicable in Numerous Multi-Billion Dollar Markets
I at \ NIAGEN™ is a Platform Ingredient Applicable in | 10 Numerous Multi-Billion Dollar Markets amy _ Infant Formulas Market Size - $8B Dietary . (Similac Supplements 1 a oes Market Size - $34B \ =. NIAGEN. ™ Medical Foods | ‘isla Market Size - $98 f if Sports Nutrition Market Size - $5B \ Commerci
Slide 11: Collaborative Agreements with Prestigious Universities for Research on NIAGEN
<) NIAGEN. i ChromaDex has Collaborative Agreements with Numerous Prestigious Universities for Research on NIAAGEN™ HARVARD mepicaLscHoo. [QL EF Washington University in St.Louis ), i iT Massachusetts MAYO. Institute of CLINIC SOE PaLTeEA NICU Technology Gy FEDERALE DE LAUSANNE Qtr L @& scniees fi f
Slide 12: NIAGEN Consumer Products
NIAGEN™ Consumer Products NIAGEN. | 12 ©
Slide 13: Caffeinated Energy Products Under Increased Regulatory and Political Scrutiny
Caffeinated Energy Products Have Been Coming Under [13 Increased Regulatory and Political Scrutiny Regarding the Possible Risks of Consuming High Amounts of Caffeine March 2012 —a Chicago City Alderman proposed banning energy drinks with at least 180 milligrams of caffeine. ‘October 2012 U.S. Senato
Slide 14: PURENERGY is Poised to Revolutionize the Energy Beverage Market
PURENERGY?® is Poised to Revolutionize the [14 Energy Beverage Market ~~ ye F plerePure + Caffeine = OO ® By cocrystallizing caffeine with ChromaDex's pTeroPure © pterostilbene, caffeine's energy boost is sustained for at least 6 hours! ® PURENERGY® also results in a more gradual finish, avoiding th
Slide 15: PURENERGY Clinical Results - 2013
PURENERGY ® Clinical Results - 2013 [15 ie. PURENERGY _ The cross-over, clinical study compared the cocrystallized caffeine in PURENERGY ® with ordinary caffeine. The findings of the study showed: + PURENERGY’® delivers almost 30% more caffeine into the blood than ordinary caffeine. + The rate of ca
Slide 16: PURENERGY Consumer Products
PURENERGY® Consumer Products }4i5B00sT S = 1S Sy PURENERGY a4
Slide 17: Blueberries Contain the Powerful Antioxidant Pterostilbene
Blueberries Contain the Powerful Antioxidant \17 Pterostilbene. ChromaDex has Commercialized its IP-backed and Clinically-studied Brand, pTeroPure® plerPure pTeroPure® is ChromaDex’s branded pterostilbene ® Pterostilbene is a phytoalexin (plant defense system) found naturally in blueberries, but onl
Slide 18: pTeroPure Phase 2/3 Clinical Study
pTeroPure® was Evaluated in a Phase 2/3 Clinical 18 Study Which Showed Statistically Significant Results for its Ability to Lower Blood Pressure plersPure Clinical trial completed at the University of Mississippi Double-blind, randomized, placebo-controlled, IRB-reviewed 80 patients, 4 arms. Eight-w
Slide 19: pTeroPure Success
pTeroPure® Success pleréPure Launched pTeroPure® brand in Sept. 2010 First ChromaDex branded ingredient 40+ products containing pTeroPure® on the market today 2H Activator é 4 é BITE: | 149
Slide 20: ProC3G - Anthocyanin
ProC3G ® - Anthocyanin fea ProC3G. Ganthopure Cyanidin-3-glucoside Overview » Anthocyanins are compounds responsible for the deep purple color in berries, flowers, black rice and other botanicals ® Specific anthocyanins have been studied more extensively and have shown promising health benefits - e.
Slide 21: ChromaDex Ingredient Patent Portfolio
ChromaDexe Ingredient Patent Portfolio |24 @ ena Patent — © Patent pending Ingredient Technology Status NIAGEN.
Slide 22: ChromaDex Ingredient Development Pipeline
ChromaDex Ingredient Development Pipeline Product Potential Benefits Year Launched in Model Pipeline Product 1 Pipeline Product 2 Bone Health, Increased Bone Density 2014 Immunity Pipeline Product 3 Heart Health/Cholesterol 2014 Pipeline Product 4 Improves Sleep 2014 Pipeline Product 5 NAD Metabolit
Slide 23: Ingredient Sales Continued to Accelerate in Q2 2014
~ «« Ingredient Sales Continued to Accelerate in Q2 2014 - | 23 t Up 155% Year-Over-Year and Up 52% Sequentially » Net ingredient sales (NIS) for Q2 2014 were $1.7 million, up 155% as compared to Q2 2013 NIS of $670K and up 52% sequentially compared to Q1 2014 NIS of $1.1 million > Total company net
Slide 24: The Natural Products Chemistry Business is a Revenue-generating Platform
‘ The Natural Products Chemistry Business is a Revenue- | 24 a. generating Platform with 15 Years of Expertise in the Ea Natural Products Industry Matural product fnalytical & Spherix consulting services fine chemicals chemistry-based services BY a \ v S < S ® Largest phytochemical ® Analytical test
Slide 25: The Natural Products Chemistry Business is Positioned for Growth
The Natural Products Chemistry Business is 125 Positioned for Growth Increased consumer demand — natural products industry expected to reach $243B by 2015! t Increased R&D by global blue-chip players — e.g. Pepsi Global Nutrition Group, Nestle Health Sciences t Increased regulatory scrutiny — FDA im
Slide 26: ChromaDex is Following the Model of Other Ingredient Technology Companies
ChromaDex is Following the Model of Other | 26 Ingredient Technology Companies MARTEKO Patented vegetarian Acquired by DSM for life enriched: ‘omega-3 ingredient $1.08B in 2010 Acquired by DSM for Fish Oil omega-3 $550M in July 2012 p — J Acquired by DSM for fortitech spared $634M in 2012 srr wren p
Slide 27: Strategic Investment from DSM Venturing in October 2013
ChromaDex Received Strategic Investment |27 from DSM Venturing in October 2013 DSM BRIGHT SCIENCE. BRIGHTER LIVING. » $2.5 million common stock investment at $0.85/share » Demonstrated DSI’s confidence in the future of ChromaDex as well as its unique business model of acquiring and commercializing n
Slide 28: ChromaDex SAB
| 28 ChromaDex SAB @ & ChromaDex established its first formal Scientific Advisory Board (SAB) in July 2014 Nobel Laureate Professor Roger Kornberg joined as Chair The other SAB members are: + Dr. Charles Brenner, Professor of Biochemistry, University of lowa (formerly Dartmouth), one of the NR inven
Slide 29: Focused Expertise / ChromaDex Highlights
ya 4 Focused Expertise if Ingredient Technology Portfolio NIAGEN a PURENERGY pleréPure ProC3G Cyanidin-2-giucoside ChromaDex Highlights | 29 ChromaDex’s natural products chemistry business continues to grow at a steady rate as it has over the past 15 years. Its expertise in the natural products indu
Slide 30: Additional Company Information
Additional Company Information APPENDIX | 30
Slide 31: ChromaDex at a Glance
}<<¢ ChromaDex at a Glance - rs a : ® Founded 1999 by CEO, Frank Jaksch ® Headquarters: Irvine, CA ® Analytical Laboratory: Boulder, CO - Acquired in April 2003 from NaPro Irvine, CA BioTherapeutics ® Regulatory Consulting: Rockville, MD - Acquired Spherix Consulting in December 2012 ® Employees: Ap
Slide 32: ChromaDex Management Team
ChromaDex Management Team | 32 Frank Jaksch Co-Founder, CEO, Dir ® Founded ChromaDex in 1999 @ Intl Subsidiaries Manager at Phenomenex. ® Expertise in analytical chemistry, productdevelopment Recognized industry expert, most recently appearing ‘on Dateline NBC's Hansen Files regarding quality testin
Slide 33: Shareholder Summary
Shareholder Summary |33 Percent Shareholder Number of Shares Ownership! Dr. Phillip Frost 15,252,937 14.32% Opko Health, Inc. (NYSE:OPK) 1,833,333 1.72% DSM Venturing B.V. 2,941,176 2.76% Frank L. Jaksch Jr. (Founder, CEO, Director) 8,243,320 1.14% Other Directors and Officers 18,571,494 17.44% Tota
Slide 34: ChromaDex Model in Action - NIAGEN
» ChromaDex Mod Case Study Acquire 4 ’ | Discover jel in Action - NIAGEN™ | 34 2006: ChromaDex | 2011: July, Licensed becomes aware of NR Camelipatens | research material 2012: July, Licensed Dartmouth patents 2013: March, Licensed! Washington University patents with Thome Research in for 3 years an
Slide 35: ChromaDex Ingredient Technology Portfolio
ChromaDex® Ingredient Technology Portfolio | 35 Monetization Branded ingredient | Compound Supply __Safety_Development_ Supplements _Beverage__Health __ Care Clinical Dietary Food& Animal Skin plerePure @ vv @ Vv eV VO e e® 0 0 0 NIAGEN. Cg Riboside v YooeoevVvVoae20Ve v Pipeline of Next-generation
Slide 36: Non-GAAP Presentation Reconciliation
Non-GAAP Presentation Reconciliation Consolidated Statements of Operations [cts a Non cash Charges associated with | 36 CConscidated Staements of Operations US GAAP) ‘Sharebased Compensation Expense Ftuaing Share based Compensation (Non-GAAP) ‘3Mons Ended June 28 2014 and June 29,2073 ‘Monts Ended J
Slide 37: Non-GAAP Presentation Reconciliation
| 37 Non-GAAP Presentation Reconciliation Consolidated Staements of Operations (Us GAAP} ‘Months Ende June 28, 204 and June 29, 208 Efe of Non-cash Charges associated with Sharebased Compensation Expense (Months Ende June 25, 2014 and ane 28, 2013. Consolidated Statonents of Operations Excluding Sha
Slide 38: Non-GAAP Presentation Reconciliation
| 38 Non-GAAP Presentation Reconciliation Consolidated Sttoments of Operations Us cAMP} ‘2 Months Ended Dec 28, 20°3and Dec. 29,2012 {Bets of Non-cash Chargs asocited with ‘Sharebased Compensation Expense ‘2Months Ended Dec. 28, 203 and Dec. 2, 2012 Consolidated Sttoments of Operations Excluding Sha
Slide 39: Contact Information
Contact Information ChromaDex, Inc. 10005 Muirlands Blvd., Suite G Irvine, CA 92618 Phone: +1-949-419-0288 Fax: +1-949-419-0294 www.chromadex.com Investor Relations Laura Kelly ChromaDex Phone: +1-949-419-0288 laurak@chromadex.com | 39 ©